OpenLegislation

Paragraph 27 F1

Instructions for proper use of the product including in particular—

(a)

the dosage;

(b)

the method of use, application, administration or implantation and, if necessary, the route of administration;

(c)

the frequency of administration (including, if necessary, specifying the times at which the product may or must be administered);

(d)

the duration of treatment if this is to be time limited;

(e)

symptoms of an overdose and the action, if any, to be taken in the case of an overdose;

(f)

what to do if one or more doses have not been taken;

(g)

a specific recommendation to consult a doctor or pharmacist, as appropriate, for further explanation of the use of the product.

Annotations

Textual amendments

F1

Sch. 27 Pt. 3 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 204(6) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 158(e)); 2020 c. 1, Sch. 5 para. 1(1)

Notes on Part 3

Textual amendments

F2

Words in Sch. 27 Pt. 3 heading omitted (1.1.2025) by virtue of The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 143(c)